THEOPHYLLINE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Theophylline, and what generic alternatives are available?
Theophylline is a drug marketed by Cent Pharms, Hospira, Inwood Labs, Sandoz, Kv Pharm, Scherer Rp, Alpharma Us Pharms, Cenci, Chartwell Rx, Halsey, Pharm Assoc, Precision Dose, Roxane, Taro, Wockhardt, Chartwell Molecular, Tris Pharma Inc, Able, Alembic, Amneal, Annora Pharma, Bionpharma, Glenmark Generics, Glenmark Pharms Ltd, Harman Finochem, Heritage Pharma Avet, Leading, Nostrum Labs Inc, Rhodes Pharms, Teva Pharms Inc, B Braun, Baxter Hlthcare, and Hospira Inc. and is included in fifty-one NDAs.
The generic ingredient in THEOPHYLLINE is theophylline. There are thirty-six drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the theophylline profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Theophylline
A generic version of THEOPHYLLINE was approved as theophylline by RHODES PHARMS on September 1st, 1982.
Summary for THEOPHYLLINE
US Patents: | 0 |
Applicants: | 33 |
NDAs: | 51 |
Finished Product Suppliers / Packagers: | 19 |
Raw Ingredient (Bulk) Api Vendors: | 170 |
Clinical Trials: | 109 |
Patent Applications: | 6,958 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for THEOPHYLLINE |
DailyMed Link: | THEOPHYLLINE at DailyMed |
Recent Clinical Trials for THEOPHYLLINE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Oklahoma | Phase 1/Phase 2 |
Medical College of Wisconsin | Phase 1/Phase 2 |
University of California, Los Angeles | Early Phase 1 |
Pharmacology for THEOPHYLLINE
Drug Class | Methylxanthine |